Category Archives: 2024

To find the article on the web: PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma   IRVINE, Calif., Dec. 19, 2024 /PRNewswire/ — PeproMene Bio, Inc. (PMB) … Continue reading →

Irvine, CA, September 20, 2024 – A lymphoma survivor talks about his treatments with CAR T-cell therapy to fight cancer | Lymphoma Awareness Month – CBS Los Angeles, originally aired on September 19, 2024.   To find the media clip … Continue reading →

Irvine, CA, September 20, 2024 – Relapsed Lymphoma Patient Thrives After CAR T Cell Trial – originally posted by City of Hope, on September 17, 2024.   To find the article on the web: https://www.cityofhope.org/relapsed-lymphoma-patient-thrives-after-car-t-cell-trial   About PMB-CT01 PMB-CT01 is … Continue reading →

IRVINE, Calif., Aug. 7, 2024 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies for cancers and immune disorders, today announced that City of Hope-developed BAFF-R CAR T, known as PMB-CT01, demonstrated better polyfunctionality than CD19 CAR T cells, which are … Continue reading →

IRVINE, Calif., Jan. 18, 2024 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic … Continue reading →